Abstract Purpose: This study was designed to evaluate the associations between angiogenesis gene polymorphisms and clinical outcome in ovarian cancer patients treated with low-dose cyclophosphamide and bevacizumab. Experimental Design: Seventy recurrent/metastatic epithelial ovarian cancer patients were enrolled in a phase II clinical trial. Genomic DNA was available from 53 blood samples. Polymorphisms were analyzed using the PCR-RFLP protocol. A 5 ¶ end 33 P gATP-labeled PCR protocol was used to analyze dinucleotide repeats. Results: Patients genotyped A/A or A/T for the IL-8 T-251A gene polymorphism had a statistically significant lower response rate (19%; 0%) than those homozygous T/T (50%; P = 0.006, Fisher's exact test). Patients carrying a minimum one C allele (C/C; C/T) of the CXCR2 C+785T polymorphism showed a median progression-free survival (PFS) of 7.4 months compared with the PFS of 3.7 months for those homozygous T/T (P = 0.026, log-rank test). Patients with the VEGF C+936T polymorphism C/Tgenotype had a longer median PFS of 11.8 months, compared with those with the C/C andT/Tgenotype, which had median PFS of 5.5 months and 3.2 months, respectively (P = 0.061, log-rank test). Patients carrying both AM 3 ¶end alleles <14 CA repeats had the shortest median PFS of 3.4 months; patients with at least one allele >14 repeats or both alleles >14 repeats showed a median PFS of 6.4 months and 7.2 months, respectively (P = 0.008, log-rank test). Conclusion: Our data suggest that the IL-8 A-251T polymorphism may be a molecular predictor of response to bevacizumab-based chemotherapy. The CXCR2 C+785T, VEGF C+936T single nucleotide polymorphisms and the AM 3 ¶ dinucleotide repeat polymorphisms may be molecular markers for PFS in ovarian cancer patients.
Ovarian cancer is the fourth most common cancer in women and the leading cause of death in gynecologic malignancies in the United States. It is estimated that f21,650 new cases will occur in 2008 and >15,520 women are expected to die of this disease (1) . Due to lack of early symptoms, f70% of ovarian cancers are diagnosed in International Federation of Gynecologic and Obstetrics stage 3 and 4 (2, 3) . Advances in surgical technique, chemotherapy, and supportive care, have all contributed to an improved 5-year survival rate approaching 45%. The standard initial chemotherapy for patients with ovarian cancer involves a platinum-paclitaxel regimen. About 70% of patients will achieve a clinical response to this therapy. However, the rate of recurrence is 62%, and <20% of the patients with stage 3 and 4 disease survive in the long term (2, 4) , implicating the need for better treatment options.
Like normal tissues, tumors require an adequate supply of oxygen, metabolites, and an effective way to remove waste products. Therefore, gaining access to the host vascular system and the generation of a tumor blood supply are rate-limiting steps in tumor growth and progression. Tumors start as avascular masses that can initially thrive on preexistent vasculature within the microenvironment. When a tumor grows beyond a size of f2 to 3 mm (5), it requires, as a consequence, its own new and dedicated vasculature. The socalled ''angiogenic switch,'' the induction of tumor vasculature, is considered a hallmark of the malignant process and is required for tumor propagation and progression. The highly complex angiogenic process is regulated by a number of proangiogenic and antiangiogenic factors and also occurs in embryogenesis, organ growth, wound healing, and many others. These physiologic processes differ from pathologic angiogenesis in which the balance of proangiogenic and antiangiogenic signals is tightly regulated. Tumors have lost the appropriate balance between positive and negative control by inducing mainly proangiogenic factors. Tumor vascularization and tumor expression of proangiogenic factors have been associated with advanced tumor stage and poor prognosis in a variety of human cancers (6 -8) .
Many proangiogenic factors have been identified; in fact, the vascular endothelial growth factor (VEGF) and its receptors are among the most important activators. Activation of the VEGF/ VEGF receptor (VEGFR) axis triggers multiple signaling transduction networks that result in endothelial cell survival, mitogenesis, migration, differentiation, vascular permeability, and mobilization of endothelial progenitor cells (5) . Induction of VEGF expression can occur through several stimuli. Hypoxia, one of the most common stimuli, induces the expression of various transcription factors (9) , such as hypoxia inducible factor 1a, which has been also closely linked to the regulation of hypoxia-driven angiogenesis and tumor growth (9 -11) . Overexpression of VEGF has been associated with tumor progression and poor prognosis in several different malignancies, including colorectal, gastric, and pancreatic carcinoma; breast, prostate, and lung cancer; and melanoma (3, 5, 9) . Preclinical studies suggest that VEGF-mediated angiogenesis is important in initiating and mediating the growth of ovarian cancers (9, 12, 13) and has been shown to be a marker of poor prognosis in these patients (6, 7) . In xenograft models of human epithelial ovarian cancer, an overexpression of VEGF was directly correlated to microvessel density (14) . It is becoming increasingly apparent that ovarian cancer is a highly angiogenic tumor. Therefore, it is regarded as a promising clinical model for the use of antiangiogenic therapies.
Chemotherapeutics, such as cyclophosphamide, do not specifically target tumor cells, but rather interfere with cell division and therefore also target normal dividing cells of the vasculature. Elimination of these dividing endothelial cells, or inhibition of mitosis, would presumably lead to an antiangiogenic effect. The efficiency of antiangiogenic chemotherapy seems to be optimized when administered at comparatively low doses on a frequent, continuous schedule with no extended interruptions, which also referred to as metronomic chemotherapy (14, 15) . This antiangiogenic effect is further escalated with the addition of specific antiangiogenic drugs, such as antibodies against VEGF (15) .
In February 2004, bevacizumab, a humanized monoclonal antibody targeting VEGF, was first approved by the Food and Drug Administration for metastatic colorectal cancer. Since then, bevacizumab has been shown to have promising activity, when combined with standard chemotherapy, in many tumor types, including lung, renal, breast, brain, and pancreatic cancers (16) . Nevertheless, disease progression eventually occurs in many patients. This raises the issue that VEGF-independent pathways may compensate for the loss of VEGF and therefore mediate sustained tumor angiogenesis. The identification of such pathways will help in furthering our ability to both understand mechanisms of resistance to anti-VEGF therapies and to develop more effective antiangiogenic therapies (17) .
In the postgenomic era, the possibility of individualizing cancer treatment by using molecular markers (e.g., germline polymorphisms) that predict the efficacy of chemotherapy is gaining wide acceptance. In our study we examined 33 germline polymorphisms within 30 genes involved in the angiogenic pathway. We analyzed genes that encode for molecules (a) with direct proangiogenic potential and/or their receptors such as VEGF, placental growth factor, VEGFR2/kinase insert domain receptor, neuropilin 1, adrenomedullin, leptin, interleukin (IL)-8, interleukin receptor 1 and 2 (CXCR1, CXCR2), insulin like growth factor 2, insulin like growth factor receptor, fibroblast growth factor receptor 4, and tissue factor; (b) with supportive effects such as matrix metalloproteinases (MMP2, MMP9, MMP7) and intercellular adhesion molecule 1; and (c) which stimulate/influence the release of direct proangiogenic factors such as epidermal growth factor, epidermal growth factor receptor, hypoxia inducible factor 1a, aryl hydrocarbon receptor nuclear translocator, IL-6, nuclear factor-nB, tumor necrosis factor-a, IL-1h, IL-1 receptor antagonist, murine double munit-2, p53, cyclooxygenase-2, and stromal cellderived factor-1 (Table 1) .
Patients and Methods
Patients. Seventy patients with histopathologically documented recurrent epithelial ovarian carcinoma or primary peritoneal carcinoma with measurable disease, by the guidelines of the Response Evaluation Criteria in Solid Tumors, were enrolled in a multicenter phase II clinical trial (PH-II-45, ref. 18 ). All patients signed a provided written informed consent consistent with current institutional, state, and federal regulations before entering the study. To participate in this study,
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patients were furthermore required to have received a platinumcontaining regimen for primary disease and up to two distinct prior regimens for recurrent disease. Patients with an initial treatment-free interval of >12 mo were required to be treated with a platinum-based regimen. Prior therapy with a taxane was not required. Performance status for each patient was classified in accordance with the Southwest Oncology Group criteria, and patients with status >2 were not eligible for this study. Projected life expectancy had to be at least 3 mo. Prior treatment with an antiangiogenic agent was not allowed. All eligible patients were included in the analyses of response, toxicity, progressionfree survival (PFS), and overall survival (OS).
Blood samples from 53 patients were available for the present molecular correlates study. All samples were collected prior to the start of chemotherapy. There was no significant difference in age, ethnicity, Southwest Oncology Group performance status, platinum sensitivity, and clinical outcome (tumor response, PFS, OS, and grade 3 to 4 toxicity) between the 53 patients analyzed and the remaining 17 patients (of 70) with no blood samples available. The median age of the patients was 59 y (range, 31-83). Forty-five patients were Caucasian, three Asian, three African American, and two Hispanic. Southwest Oncology Group performance status was 0 for 27 patients, 1 for 22 patients, and 2 for 4 patients. Detailed demographic and clinical characteristics and the clinical outcome of study patients are summarized in Table 2 .
Treatment protocol. All patients were treated with i.v. bevacizumab and oral cyclophosphamide. During the first 3 wk of treatment, bevacizumab was administered i.v. at a dose of 10 mg/kg every week followed by administration every 2 wk. Oral cyclophosphamide was taken at a daily dose of 50 mg. A cycle of treatment lasted 28 d. Treatment was continued until the patient experienced tumor progression or toxicity, or until its termination upon patient request/physician discretion. Evaluation of toxicity took place every 2 wk and was graded according to the NIH common toxicity criteria, version 3.0. Assessment of response was evaluated after every two cycles of treatment.
Candidate polymorphisms. The polymorphisms we tested were selected via a ''horizontal'' and ''vertical'' pathway approach with the goal of selecting genes known to modulate VEGF and VEGFindependent angiogenesis (Table 1; Supplementary Table S1 ). We used the following criteria to select genes for study: (a) that the gene be part of a pathway for which there is a credible scientific basis to support its involvement in the angiogenesis signaling pathway; (b) that the gene has an established, well-documented genetic polymorphism; (c) that the frequency of the polymorphism is high enough that its effect on clinical outcome will be meaningful; and/or (d) that the polymorphism has some degree of likelihood to alter the function of the gene in a biologically relevant manner.
Genotyping. Genomic DNA was extracted from peripheral WBC using the QIAamp kit (Qiagen). The samples were tested using a PCR-RFLP technique. Briefly, forward and reverse primers were used for PCR amplification; PCR products were digested by restriction enzymes (New England Biolab); alleles were separated on 4% NuSieve ethidium bromide stained agarose gel and/or samples were analyzed by direct sequencing.
The dinucleotide polymorphisms were determined by a 5 ¶-end 33 P gATP labeled PCR protocol with a few modifications. DNA template, deoxyribonucleotide triphosphates, 5 ¶-end 33 P gATP-labeled primer, unlabeled complementary primer, Taq Polymerase (Perkin-Elmer, Inc.), and PCR Buffer were used together in a final PCR. The reaction was carried out, and the reaction products were separated on a 6% denaturing polyacrylamide DNA sequencing gel, which then was vacuum-blotted for 1 h at 80jC and exposed to a XAR film (EastmanKodak Co.) overnight. In addition, the exact number of repeats was confirmed by direct sequencing.
Statistical analysis. The primary objective of this trial was to determine PFS after 6 mo. The primary end point of this study was PFS (defined as the period beginning on the first day of treatment and ending with the first observation of disease progression or death from any cause). If a patient had not progressed or died, PFS was censored at the time of the last follow-up. The secondary end points included the response rate, toxicity, and OS. Our study considered the additive effects on clinical outcome of the genotypes for all of the single nucleotide polymorphisms tested. The adrenomedullin (CA) n repeat was analyzed by categorizing the patients into three groups: (a) patients carrying both alleles <14 repeats; (b) patients carrying one allele <14; and (c) patients carrying both alleles z14 repeats. The association between each gene polymorphism and response was evaluated by Fisher's exact test. The association between polymorphisms and PFS and OS was examined using Kaplan-Meier plots and log-rank test. In the univariate survival analysis, the Pike estimate of relative risk and its associated 95% confidence interval were based on the log-rank test. Probability of PFS at 6 mo and its Greenwood SE and median PFS and its 95% confidence interval were calculated. Cox proportional hazards regression model was used to reevaluate the association between each polymorphism and PFS, stratified by sensitivity to previous platinum-based therapy. No adjustment for multiple comparisons was done because this study was exploratory in nature and conducted to generate hypothesis for future studies. All findings should be confirmed in large independent and prospective studies before they are used to guide patient care. All statistical tests were two-sided. Analyses were done using the SAS statistical package version 9.1 (SAS Institute, Inc.).
Results
Clinical outcome. Twelve of 53 (23%) patients had a partial response. Forty-one patients were nonresponders; among them, 33 (62%) had stable disease and 8 (15%) patients had progressive disease. The median PFS for 53 patients was 6.6 months (95% confidence interval, 3.9-8.2). The median OS was 14.4 months (95% confidence interval, 11.1-21.2) with median follow-up of 32.2 months (range, 3.7-36.6; Table 2 ).
PFS associated with the CXCR2 C+785T polymorphism. Twenty-one of 53 (40%) patients were homozygous C/C at the CXCR2 C+785T gene locus; 18 patients (34%) were heterozygous C/T, and 14 patients (26%) were homozygous for the T/T variation. Patients carrying at least one C allele (C/C; C/T) showed a median PFS of 7.4 months. Patients that were homozygous T/T had a PFS of only 3.7 months (P = 0.026, log-rank test; Fig. 1A ; Supplementary Table S1) .
PFS associated with the VEGF C+936T polymorphism. Thirtyseven of 53 patients (69.8%) were homozygous for the C/C genotype, 14 (26,4%) were heterozygous C/T, and 2 were homozygous T/T. Median PFS was 11.8 months for patients heterozygous C/T, 5.5 months for patients homozygous C/C, and 3.2 months for patients being homozygous T/T (P = 0.061 log-rank test; Fig. 1B; Supplementary Table S1 ).
PFS associated with the adrenomedullin repeat polymorphism. The dinucleotide repeat polymorphism showed a range between 11 and 21 repeats. Nine of 53 patients (17%) were positive for both alleles <14 CA repeats, 16 patients (30%) had at least one allele <14 repeats (the other one could have 14 or more repeats), and 28 patients (53%) were genotyped with both alleles z 14 CA repeats. Patients carrying both adrenomedullin 3 ¶end alleles <14 CA repeats had a median PFS of 3.4 months; patients with at least one allele z 14 CA repeats showed a median PFS of 6.4 months; for both alleles z 14 CA repeats, patients showed 7.2 months of median PFS (P = 0.008 log-rank test; Fig. 1C ; Supplementary Table S1) .
Association between IL-8 T-251A polymorphism and response to chemotherapy. Thirteen of 53 patients were homozygous A/A (24.6%), 26 were heterozygous A/T (49%), and 14 were . Exon 5 C3954T . T allele higher production of IL-1h Table S1 ).
Association between the germline polymorphisms and overall survival and toxicity. No statistically significant association was found between OS or toxicity of any of the tested polymorphisms.
Discussion
The purpose of this study was to evaluate the significance of genomic variations of different genes involved in the angiogenesis pathway that may be associated with therapy efficacy. Our pilot study showed that a germline polymorphism in the IL-8 gene, which consists of a T to A substitution at position -251, was associated with response to metronomic cyclophosphamide and bevacizumab-based chemotherapy in patients with recurrent ovarian cancer or primary peritoneal carcinoma. Previously, Hull et al. had found that the A variant of this polymorphism was associated with increased IL-8 production (19) . These findings correlate with our data showing that patients carrying at least one A allele, hypothesized as having increased IL-8 production, had a statistically significant lower response rate than those being homozygous for the wild type (T-allele). As previously shown by our group, IL-8 T-251A and its receptor CXCR-1 were associated with clinical outcome in colorectal cancer patients. High-expression variants of IL-8 T-251A were found to be significantly associated with the risk of recurrence in colon and rectal cancer patients in both univariate and multivariable analysis (20, 21) . Other studies reported that IL-8 plays a significant role in mediating human ovarian carcinoma -derived angiogenesis and tumorigenesis (22) . Il-8 exerts its potent angiogenic properties on endothelial cells through interaction with its cognate receptors CXCR1 and CXCR2 (17, 22 -24) . Induction of IL-8 preserved the angiogenic response in hypoxia inducible factor 1a -deficient colon cancer cells, suggesting that IL-8 mediates angiogenesis independently of VEGF (25) . These studies support our hypothesis that overexpression of IL-8 may be responsible for resistance to bevacizumab-based chemotherapy. Therefore, IL-8 may be a promising novel target for drug development. In vitro and in vivo data suggest that the combination of VEGF and IL-8 antibodies has a synergistic effect (24), further supporting the significance of IL-8.
In addition, we showed that the CXCR2 C+785T polymorphism was associated with PFS in our patient cohort. CXCR2 functions as a receptor for IL-8 on endothelial cells, thus providing more evidence for IL-8 -induced angiogenesis. Furthermore, in human intestinal micro vascular endothelial cells, IL-8 mediated its angiogenic potential via CXCR2 signaling (23) . CXCR2 knock-out mice, in a murine model of lung cancer, showed reduced tumor growth, increased tumorassociated necrosis, and reduced metastatic potential in an angiogenesis-dependent manner, again supporting the role of IL-8 and CXCR2 in angiogenesis (22) . Inhibition of this chemokine receptor decreased pancreatic cancer cell -induced angiogenesis. Strong expression of CXCR2 was found on ovarian cancer cells (17) , indicating that IL-8 and its receptor signaling -induced angiogenesis play a role in ovarian cancer. Thus far, the functional significance of the CXCR2 C+785T polymorphism remains unclear. However, previous studies have reported an association between this polymorphism and systemic sclerosis and cryptogenic fibrosing alveolitis (26) . On the other hand, this polymorphism may be in linkage disequilibrium with other functional polymorphisms that are responsible for this significant association. Taken together, these data suggest the importance of the IL-8 pathways in the angiogenesis of ovarian tumors.
We could also show an association between a polymorphism in the gene encoding for adrenomedullin and PFS, indicating a potential role of adrenomedullin in ovarian cancer angiogenesis. Adrenomedullin, which was originally identified as a vasodilatatory peptide, has been later described as a proangiogenic factor (27) . Previously, Nikitenko et al. described the role of adrenomedullin in tumor angiogenesis (28, 29) . Adrenomedullin mediates its signals via a G-protein coupled receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins have been recognized as integral components of the adrenomedullin signaling system. Recent studies have shown that adrenomedullin activates the PIK/Akt-dependent pathway in vascular endothelial cells, independently of VEGF. This pathway is considered to regulate endothelial cell survival, proliferation, migration, and capillary-like structure formation (30) . VEGF and adrenomedullin have been found to act synergistically to induce angiogenic-related effects on endothelial cells in vitro (30) . However, blockade of VEGF with antibodies could not inhibit adrenomedullin-induced capillary tube formation by human umbilical vein endothelial cells (30) , suggesting the VEGF-independent role of adrenomedullin in tumor-associated angiogenesis. Adrenomedullin-overexpressing tumors are characterized by increased vascularity. In fact, increased expression of adrenomedullin mRNA in ovarian tumors has been associated with poor prognosis and histopathologic grade (2, 31) . In our study, we examined a CA dinucleotide repeat polymorphism in the 3 ¶-UTR region of the gene. This polymorphism was found to be associated with a genetic predisposition to essential hypertension and type 2 diabetes in patients with renal failure (32, 33) . Thus far, there are no data available concerning the exact function of this repeat. Nevertheless, our data indicate that adrenomedullin may play a role in VEGF-independent angiogenesis of ovarian tumors. VEGF regulates blood and lymphatic vessel development and homeostasis. Under nonmalignant conditions, it is predominantly produced by endothelial, hematopoietic, and stromal cells in response to hypoxia and upon stimulation with growth factors such as transforming growth factor, interleukins, and/or platelet-derived growth factor. VEGF, specifically the VEGF165 isoform, is a major regulator of tumor-associated angiogenesis and promotes tumor growth, invasion, and metastasis. Its expression level in cancer cells directly correlates with tumor size, metastasis, and poor prognosis in many types of solid and hematologic tumors (34, 35) . Several functional polymorphisms in the VEGF gene have been described (36) . In our study, we found an association between the VEGF C+936T polymorphism and PFS. This polymorphism is located in the 3 ¶-UTR of the gene. The T variant of this polymorphism was associated with significantly lower VEGF plasma levels (37). In our study, patients carrying both alleles of the T variant had a significant shorter median PFS than those being homozygous or heterozygous for the wild type (C/T, C/C). Although conflicting results have been reported (38) , a recent study showed that the prevalence of the VEGF C+936T T-allele, which is associated with decreased plasma levels of VEGF, was less common in breast cancer patients than in healthy subjects, indicating that this genetic variant may be protective against breast cancer (39) . In addition, VEGF gene polymorphisms were found to be independent prognostic markers in patients with surgically resected gastric, lung, and colon cancer (21, 40, 41) . These findings support the hypothesis that the expression of VEGF and specifically functional polymorphisms in the VEGF gene may play a role in the efficacy of anti-VEGF therapies.
In this pilot study, we showed for the first time that genetic variations in genes involved in ovarian tumor angiogenesis are associated with response and PFS in patients treated with bevacizumab-based chemotherapy, independent of platinum sensitivity of initial platinum-based therapy (Table 3) . Furthermore, our data suggest an important role of genes independent of VEGF to play a critical role in the mechanism of resistance to anti-VEGF therapy. Larger prospective clinical trials are needed to confirm and validate our preliminary findings.
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